arrow
A

Ann Mullally

medicine
H指数:37
被引数:7,720

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing

突变SRSF2相关的红细胞生成障碍是由FYN剪接错误导致的mTORC1信号增强所定义。

Leukemia
IF13.4
2026-02-260
PRE
Risk stratification of patients with TP53-mutated myeloproliferative neoplasms

TP53突变骨髓增殖性肿瘤患者的风险分层

Leukemia
IF13.4
2026-02-240
PRE
ZRSR2 loss causes aberrant splicing in JAK2V617F-driven myeloproliferative neoplasm but is not sufficient to drive disease progression

ZRSR2缺失导致JAK2V617F驱动的骨髓增殖性肿瘤中发生异常剪接,但不足以驱动疾病进展。

2025-09-160
OAAI
Trial-in-Progress: A Phase 2 Study of Ruxolitinib in Low-Risk Essential Thrombocythemia and Polycythemia Vera Patients with High Symptom Burden

进行中的试验:一项关于芦可替尼在具有高症状负担的低危原发性血小板增多症和真性红细胞增多症患者中的II期研究

BLOOD
IF23.1
2024-11-050
PRE
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine

钙网蛋白突变体骨髓增生性肿瘤诱导mhc-i偏斜,这可以通过优化的肽癌症疫苗来克服

2022-06-1512
PRE
Genomic profiling of a randomized trial of interferon-a vs hydroxyurea in MPN reveals mutation-specific responses
2022-03-3031
OAAI
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms
2021-03-01133
OAAI
MHC-I SKEWING IN MUTANT CALRETICULIN-POSITIVE MYELOPROLIFERATIVE NEOPLASMS IS COUNTERED BY HETEROCLITIC PEPTIDE CANCER VACCINATION
2020-11-090
OAAI